Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral it in‑licensed to prevent COPD exacerbations tied to rhinovirus infections; Forbion led the round and Sanofi participated. Altesa plans a Phase 2b study enrolling roughly 900 COPD patients who will be randomized at the time of rhinovirus infection, aiming to show prevention of severe exacerbations. Sanofi’s participation adds strategic support around respiratory and COPD expertise; Altesa says the financing will fund the Phase 2b and related development activities. The move revives a previously failed rhinovirus asset with a new target population and trial design.